Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies
Executive Summary
The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.